Gapping down
In reaction to earnings/guidance:
- EPAM -14.1%
Select pharma/biotech names showing weakness following ASCO presentations:
- CSTL -9.2%, RCUS -7.1%, ELTX -3.6%
Select stocks showing early weakness following index changes:
- RYAM -5.3%, CARA -4.2%, ZUMZ -4.1%, PLCE -3.7%, DOUG -3.7%, LPSN -3.5%, CMTL -3.1%, GCI -3.1%, TREE -3.1%, TG -3.1%, INGN -3.1%, BOOM -2.7%, EGRX -2.5%, FARO -2.4%, GCO -2.1%, PETS -1.7%, BIG -1%
Other news:
- BLPH -73.8% (Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse)
- LDI -6.3% (announces organizational changes, names new CFO)
- DISH -4.4% (PANW will replace DISH Network (DISH) in the S&P 500)
- BEEM -1.8% (files for $150 mln mixed securities shelf offering)
- DEO -1.8% (appoints Debra Crew interim CEO after Ivan Menezes has medical setback)
Analyst comments:
- BPMC -2.5% (downgraded to Underperform from Market Perform at SVB Securities)
- DG -1.2% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- EL -1% (downgraded to Perform from Outperform at Oppenheimer)
- TGT -0.8% (downgraded to Sector Weight from Overweight at KeyBanc Capital Markets)